• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RNA剪接突变在弥漫性大B细胞淋巴瘤中的作用

Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma.

作者信息

Berta Dereje, Girma Mekonnen, Melku Mulugeta, Adane Tiruneh, Birke Bisrat, Yalew Aregawi

机构信息

Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Department of Quality Assurance and Laboratory Management, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

出版信息

Int J Gen Med. 2023 Jun 15;16:2469-2480. doi: 10.2147/IJGM.S414106. eCollection 2023.

DOI:10.2147/IJGM.S414106
PMID:37342407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10278864/
Abstract

Ribonucleic acid splicing is a crucial process to create a mature mRNA molecule by removing introns and ligating exons. This is a highly regulated process, but any alteration in splicing factors, splicing sites, or auxiliary components affects the final products of the gene. In diffuse large B-cell lymphoma, splicing mutations such as mutant splice sites, aberrant alternative splicing, exon skipping, and intron retention are detected. The alteration affects tumor suppression, DNA repair, cell cycle, cell differentiation, cell proliferation, and apoptosis. As a result, malignant transformation, cancer progression, and metastasis occurred in B cells at the germinal center. B-cell lymphoma 7 protein family member A (BCL7A), cluster of differentiation 79B (CD79B), myeloid differentiation primary response gene 88 (MYD88), tumor protein P53 (TP53), signal transducer and activator of transcription (STAT), serum- and glucose-regulated kinase 1 (SGK1), Pou class 2 associating factor 1 (POU2AF1), and neurogenic locus notch homolog protein 1 (NOTCH) are the most common genes affected by splicing mutations in diffuse large B cell lymphoma.

摘要

核糖核酸剪接是通过去除内含子并连接外显子来产生成熟mRNA分子的关键过程。这是一个高度受调控的过程,但剪接因子、剪接位点或辅助成分的任何改变都会影响基因的最终产物。在弥漫性大B细胞淋巴瘤中,可检测到剪接突变,如突变剪接位点、异常可变剪接、外显子跳跃和内含子保留。这种改变会影响肿瘤抑制、DNA修复、细胞周期、细胞分化、细胞增殖和细胞凋亡。结果,生发中心的B细胞发生恶性转化、癌症进展和转移。B细胞淋巴瘤7蛋白家族成员A(BCL7A)、分化簇79B(CD79B)、髓样分化初级反应基因88(MYD88)、肿瘤蛋白P53(TP53)、信号转导和转录激活因子(STAT)、血清和葡萄糖调节激酶1(SGK1)、POU2类相关因子1(POU2AF1)以及神经源性位点Notch同源蛋白1(NOTCH)是弥漫性大B细胞淋巴瘤中受剪接突变影响最常见的基因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/274f5d9b028b/IJGM-16-2469-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/63002e9bc31e/IJGM-16-2469-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/4c3ccdb4bd05/IJGM-16-2469-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/662ec6cecc45/IJGM-16-2469-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/274f5d9b028b/IJGM-16-2469-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/63002e9bc31e/IJGM-16-2469-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/4c3ccdb4bd05/IJGM-16-2469-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/662ec6cecc45/IJGM-16-2469-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8308/10278864/274f5d9b028b/IJGM-16-2469-g0004.jpg

相似文献

1
Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma.RNA剪接突变在弥漫性大B细胞淋巴瘤中的作用
Int J Gen Med. 2023 Jun 15;16:2469-2480. doi: 10.2147/IJGM.S414106. eCollection 2023.
2
Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.对感染蜱传脑炎病毒(TBEV)的神经元和星形胶质细胞进行的综合RNA分析揭示了潜在的致病效应物。
Comput Struct Biotechnol J. 2022 May 30;20:2759-2777. doi: 10.1016/j.csbj.2022.05.052. eCollection 2022.
3
MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.MYD88、CARD11和CD79B致癌突变在印度初发性淋巴结弥漫性大B细胞淋巴瘤队列中是罕见事件。
Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):311-318. doi: 10.1097/PAI.0000000000000585.
4
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.CD5阳性弥漫性大B细胞淋巴瘤中的MYD88、CD79B和CARD11基因突变
Cancer. 2017 Apr 1;123(7):1166-1173. doi: 10.1002/cncr.30404. Epub 2016 Dec 4.
5
Global control of aberrant splice-site activation by auxiliary splicing sequences: evidence for a gradient in exon and intron definition.辅助剪接序列对异常剪接位点激活的全局调控:外显子和内含子定义梯度的证据。
Nucleic Acids Res. 2007;35(19):6399-413. doi: 10.1093/nar/gkm680. Epub 2007 Sep 18.
6
Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention.通过外显子跳跃和内含子保留实现人类剪接因子激酶 CLK1 的自身调控。
Gene. 2018 Sep 5;670:46-54. doi: 10.1016/j.gene.2018.05.095. Epub 2018 May 24.
7
Regulation of the MIR155 host gene in physiological and pathological processes.miR-155 宿主基因在生理和病理过程中的调控。
Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14.
8
In vivo effects on intron retention and exon skipping by the U2AF large subunit and SF1/BBP in the nematode Caenorhabditis elegans.在秀丽隐杆线虫中,U2AF 大亚基和 SF1/BBP 对内含子保留和外显子跳跃的体内作用。
RNA. 2011 Dec;17(12):2201-11. doi: 10.1261/rna.027458.111. Epub 2011 Oct 27.
9
Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.在透明质酸合酶 1 (HAS1) 基因迷你基因中内含子的改变将前体 mRNA [校正] 剪接转化为多发性骨髓瘤 (MM) 中的异常模式:MM 患者具有相似的改变。
PLoS One. 2013;8(1):e53469. doi: 10.1371/journal.pone.0053469. Epub 2013 Jan 3.
10
CD79B and MYD88 mutations in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中的 CD79B 和 MYD88 突变。
Hum Pathol. 2014 Mar;45(3):556-64. doi: 10.1016/j.humpath.2013.10.023. Epub 2013 Oct 31.

本文引用的文献

1
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的遗传亚型简化算法。
Signal Transduct Target Ther. 2023 Apr 10;8(1):145. doi: 10.1038/s41392-023-01358-y.
2
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL.复发难治性弥漫性大B细胞淋巴瘤的耐药机制及新的靶向药物与治疗方法
Cancer Manag Res. 2023 Feb 25;15:245-255. doi: 10.2147/CMAR.S400013. eCollection 2023.
3
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
基于转录组的新型免疫相关表观遗传特征可预测弥漫性大 B 细胞淋巴瘤患者的预后和治疗反应。
Clin Immunol. 2022 Oct;243:109105. doi: 10.1016/j.clim.2022.109105. Epub 2022 Aug 31.
4
PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤中与不同分子特征、表型和药物反应相关的PIM1基因改变。
Clin Transl Med. 2022 Apr;12(4):e808. doi: 10.1002/ctm2.808.
5
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment.将弥漫性大 B 细胞淋巴瘤的生物学特性转化为治疗方法。
Oncologist. 2022 Feb 3;27(1):57-66. doi: 10.1093/oncolo/oyab004.
6
Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma.免疫治疗耐药的分子机制——弥漫性大 B 细胞淋巴瘤认识和管理的进展。
Int J Mol Sci. 2022 Jan 28;23(3):1501. doi: 10.3390/ijms23031501.
7
SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.SGK1 突变状态可进一步将生发中心 B 细胞样弥漫性大 B 细胞淋巴瘤患者分为不同的预后亚组。
Cancer Med. 2022 Mar;11(5):1281-1291. doi: 10.1002/cam4.4550. Epub 2022 Feb 1.
8
Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes.复发性剪接位点突变影响关键的弥漫性大B细胞淋巴瘤基因。
Blood. 2022 Apr 14;139(15):2406-2410. doi: 10.1182/blood.2021011708.
9
Alternative Splicing in Myeloid Malignancies.髓系恶性肿瘤中的可变剪接
Biomedicines. 2021 Dec 6;9(12):1844. doi: 10.3390/biomedicines9121844.
10
Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.通过循环肿瘤 DNA 追踪未经治疗的中高危弥漫性大 B 细胞淋巴瘤的演变。
Br J Haematol. 2022 Feb;196(3):617-628. doi: 10.1111/bjh.17894. Epub 2021 Oct 19.